Status:
UNKNOWN
The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19
Lead Sponsor:
Tongji Hospital
Conditions:
COVID-19
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
PHASE3
Brief Summary
In December 2019,a new type of pneumonia caused by the coronavirus (COVID-2019) broke out in Wuhan ,China, and spreads quickly to other Chinese cities and 28 countries. More than 70000 people were inf...
Eligibility Criteria
Inclusion
- Aged between 18 and 75 years, extremes included, male or female
- Patients diagnosed with mild or common type COVID-19, according to the official guideline "Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection (Trial Version 6)"
- patients can generally tolerable for treatment recommended by the official guideline "Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection (Trial Version 6)"
- Patients have not been accompanied by serious physical diseases of heart, lung, brain, etc.,Eastern Cooperative Oncology Group score standard:0-1
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion
- Female subjects who are pregnant or breastfeeding.
- patients who are allergic to this medicine
- patients meet the contraindications of Huaier granule
- Patients with diabetes
- Patients have any condition that in the judgement of the Investigators would make the subject inappropriate for entry into this study.
- patients can't take drugs orally
Key Trial Info
Start Date :
April 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2020
Estimated Enrollment :
550 Patients enrolled
Trial Details
Trial ID
NCT04291053
Start Date
April 1 2020
End Date
September 1 2020
Last Update
March 17 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.